ReviewInternational journal of clinical pharmacy2011
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.
Review in International journal of clinical pharmacy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Design and methods of the 'monitoring outcomes of psychiatric pharmacotherapy' (MOPHAR) monitoring program - a study protocol.BMC health services research · 2019Article
- Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
- Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?International journal of clinical pharmacy · 2015Article
- Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.Mayo Clinic proceedings · 2015Article
- Improving data and knowledge management to better integrate health care and research.Journal of internal medicine · 2013Article
- Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet?British journal of clinical pharmacology · 2013Review
- Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.International journal of clinical pharmacy · 2012Article
- Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises.Current atherosclerosis reports · 2011Review
- Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Review
- Bioinformatics challenges for personalized medicine.Bioinformatics (Oxford, England) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the reviewThe translation of evidence based medicine to a specific patient presents a considerable challenge. We present by means of the examples nortriptyline, tramadol, clopidogrel, coumarins, abacavir and antipsychotics the discrepancy between available pharmacogenetic information and its implementation in daily clinical practice.
methodLiterature review.
resultsA mechanism based approach may be helpful to personalize medicine for the individual patient to which pharmacogenetics may contribute significantly. The lack of consistency in what we accept in bioequivalence and in pharmacogenetics of drug metabolising enzymes is discussed and illustrated with the example of nortriptyline. The impact of pharmacogenetics on examples like tramadol, clopidogrel, coumarins and abacavir is described. Also the present status of the polymorphisms of 5-HT2A and C receptors in antipsychotic-induced weight gain is presented as a pharmacodynamic example with until now a greater distance to clinical implementation.
conclusionThe contribution of pharmacogenetics to tailor-made pharmacotherapy, which especially might be of value for patients deviating from the average, has not yet reached the position it seems to deserve.
Indexed as
Identifiers
21365387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.